Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Pancreatic Cancer Recurrence Linked to Spatial Immune Drivers in Gut Study

Gut reports that spatially restricted tumor and host immune signals correlate with where pancreatic cancer recurs, pointing to local immune geography.

By Dr. Revathy Mohan V.R., MBBS · Oct 20, 2026 · 5 min read

Oncology·Gut

Immune Checkpoint Inhibitor Resistance Mechanisms Drive Next-Gen Cancer Therapy

A review details primary and acquired resistance to immune checkpoint inhibitors, from antigen presentation failure to immune exclusion…

Oct 20, 2026

Oncology·Gut

Lactylation Links Tumor Metabolism to Immune Escape in Cancer

A review details how lactylation reshapes tumor growth, immune evasion, and early therapeutic targeting across the lactate axis.

Oct 20, 2026

Oncology·Nature

Ovarian Cancer NETs Link Venous Thrombosis to Tumor-Driven Inflammation

Ovarian cancer patients showed higher circulating NETs, linked to venous thrombosis, poorer prognosis, and platelet elevation in a…

Oct 20, 2026

Oncology·ACC-PRO

Dual-Payload ADCs Define a New Roadmap for Therapeutic Development

A 7-step translational roadmap ties unmet need to drug design, using dual-payload ADCs as a model for resistance-informed…

Oct 20, 2026

Oncology·KFF

China Drug Access Lures U.S. Cancer Patients Seeking Sunvozertinib

American cancer patients are traveling to China for sunvozertinib and trial access as FDA delays, biotech competition, and…

Oct 20, 2026

Oncology·JCO

DCIS Lumpectomy Margins Under Patient-Level Review in JCO Study

A JCO analysis examines whether patient-level evidence supports the current 2 mm margin standard after lumpectomy for DCIS.

Oct 20, 2026

Oncology·JCO

Industry Payments Linked to Guideline-Preferred Cancer Treatment Use

Medicare analysis found oncologist industry payments were linked to higher use of promoted cancer treatments, including guideline-preferred options.

Oct 20, 2026

Oncology·JCO

Trastuzumab Botidotin Tops T-DM1 in HER2-Positive Advanced Breast Cancer

Phase III trial found trastuzumab botidotin significantly improved progression-free survival versus trastuzumab emtansine in HER2-positive advanced breast cancer.

Oct 20, 2026

Oncology·JCO

Low-dose radiotherapy helps salvage immunotherapy-resistant SMARCA4 NSCLC

A case report describes durable disease control in immunotherapy-resistant SMARCA4-deficient lung cancer after multimodal salvage therapy with low-dose…

Oct 20, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.